KR20070054764A - Manufacturing method of black rootlets of ginseng - Google Patents
Manufacturing method of black rootlets of ginseng Download PDFInfo
- Publication number
- KR20070054764A KR20070054764A KR1020050112633A KR20050112633A KR20070054764A KR 20070054764 A KR20070054764 A KR 20070054764A KR 1020050112633 A KR1020050112633 A KR 1020050112633A KR 20050112633 A KR20050112633 A KR 20050112633A KR 20070054764 A KR20070054764 A KR 20070054764A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- weight
- process steps
- black
- hours
- Prior art date
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 74
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 72
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 72
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 241000208340 Araliaceae Species 0.000 title claims abstract 11
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 35
- 238000010025 steaming Methods 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 abstract description 24
- 150000007949 saponins Chemical class 0.000 abstract description 24
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 19
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 abstract description 3
- 239000011593 sulfur Substances 0.000 abstract description 3
- 240000004371 Panax ginseng Species 0.000 description 63
- 238000004128 high performance liquid chromatography Methods 0.000 description 34
- 235000017709 saponins Nutrition 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 241001122767 Theaceae Species 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000009471 action Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 5
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940107131 ginseng root Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 3
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 3
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 3
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 3
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 3
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 3
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 3
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 3
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 3
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- SKPPEIDJGJGRGK-UHFFFAOYSA-N Panacen Natural products CCC1=CC=CC2=C1C1OC(C=C=CBr)CC1O2 SKPPEIDJGJGRGK-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001518 anti-nephritic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 108091008723 corticosteroid receptors Proteins 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001163 intracellular calcium accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 흑진삼 제조방법 및 그를 이용하여 제조된 흑진삼에 관한 것으로, 보다 구체적으로는 용매에 황기 20중량%, 사삼 20중량%, 오가피 20중량%, 맥문동 17 중량%, 복령 16 중량% 및 건강 7 중량%를 넣고 가열농축한 농축액에 홍삼을 침윤시킨 후 증숙 및 건조를 9회 이상 반복하여 보다 많은 사포닌을 함유하는 흑진삼을 제조하는 방법 및 그를 이용하여 제조된 흑진삼에 관한 것이다.The present invention relates to a method for producing black ginseng and black ginseng prepared by using the same, more specifically, 20% by weight of sulfur, 20% by weight of ginseng, 20% by weight of Ogapi, 17% by weight of Macmundong, 16% by weight of Bokryeong and The present invention relates to a method for producing black ginseng containing more saponin by infiltrating red ginseng into a concentrated solution heated to 7% by weight, followed by steaming and drying at least 9 times, and a black ginseng prepared by using the same.
흑진삼, 증숙, 건조, 사포닌, 인삼 Black Ginseng, Steamed, Dried, Saponin, Ginseng
Description
본 발명은 흑진삼 제조방법 및 그를 이용하여 제조된 흑진삼에 관한 것으로, 보다 구체적으로는 용매에 황기 20중량%, 사삼 20중량%, 오가피 20중량%, 맥문동 17 중량%, 복령 16 중량% 및 건강 7 중량%를 넣고 가열농축한 농축액에 홍삼을 침윤시킨 후 증숙 및 건조를 9회 이상 반복하여 보다 많은 사포닌을 함유하는 흑진삼을 제조하는 방법 및 그를 이용하여 제조된 흑진삼에 관한 것이다.The present invention relates to a method for producing black ginseng and black ginseng prepared by using the same, more specifically, 20% by weight of sulfur, 20% by weight of ginseng, 20% by weight of Ogapi, 17% by weight of Macmundong, 16% by weight of Bokryeong and The present invention relates to a method for producing black ginseng containing more saponin by infiltrating red ginseng into a concentrated solution heated to 7% by weight, followed by steaming and drying at least 9 times, and a black ginseng prepared by using the same.
고려인삼(Panax ginseng C.A. Meyer)은 옛날부터 한방 의학에서 최고의 영약으로 신비스러운 약효는 다른 생약의 추종을 불허하는 천하의 명초로 인식되어 왔다. 우리 선조들이 동양을 지배하는 최고의 무역상이 된 것도 인삼 및 홍삼의 신비한 효능 때문인 것으로 전하여지고 있을 정도이다. 홍삼 및 인삼의 연구가 가속화되고 국제 인삼 심포지움이 개최된 것은 홍삼의 우수성에 의한 결과로 볼 수 있다. 홍삼의 성분에는 탄수화물과 아미노산, 사포닌, 그리고 지방산으로서 스테아린산, 팔미틴산, 올레인산이 있고, 홍삼 특유의 향인 휘발성 물질은 파네센(Panacene)이라는 물질로 알려져 있다. 홍삼 사포닌은 홍삼 수용액을 흔들 때 지속적인 거품을 일으키는 식물성분을 말하는 것으로 홍삼의 약효에 관여하는 물질이라고 인식되고 있다. 인삼이나 홍삼은 전체 중량의 약 60%를 차지하는 중심부 몸통에서는 사포닌이 소량만 검출되고, 대부분의 사포닌은 잔뿌리, 외주피 및 피층에 존재하고 있는 것으로 알려져 있으며, 대형인삼은 소형인삼에 비하여 사포닌 함유 비율이 적고, 부위별 사포닌 함량은 주근부에서 1.9%, 그리고 측근부에서 4.8%가 함유되어 있음이 확인되고 있으며, 쓴맛이 강한 것은 사포닌 함량이 높은 것으로 효능도 높아서 치료 기능 또한 높은 것으로 알려지고 있다. 총 사포닌 함량으로 볼 때는 4년근은 2.84%, 6년근은 2.19로, 약 30%의 차이를 보이고 있으나 사포닌의 종류에 따른 함량은 4∼6년근에 들쭉날쭉하여 우열을 판단할 수는 없다.Korean ginseng (Panax ginseng C.A. Meyer) has long been recognized as the best medicine in herbal medicine, and the mysterious medicinal effect has been recognized as the origin of the world unmatched by other herbal medicines. It is said that our ancestors became the best traders in the East because of the mysterious effects of ginseng and red ginseng. Red ginseng and ginseng research accelerated and the international ginseng symposium was held due to the excellence of red ginseng. Red ginseng contains carbohydrates, amino acids, saponins, and fatty acids such as stearic acid, palmitic acid, and oleic acid, and the volatile substance unique to red ginseng is known as panacene. Red ginseng saponin refers to a plant component that causes continuous foaming when shaking red ginseng aqueous solution and is recognized as a substance that is involved in the efficacy of red ginseng. Ginseng and red ginseng are found in small amounts of saponin in the trunk, which accounts for about 60% of the total weight. Most saponins are known to be present in the roots, outer skin and cortex, and large ginseng contains saponin compared to small ginseng. It is confirmed that the content of saponin is less than 1.9% in the main root and 4.8% in the inner part, and the bitterness is high in saponin and high in efficacy. The total saponin content is 2.84% for 4 years and 2.19 for 6 years, showing a difference of about 30%. However, the content of saponins is jagged at 4 to 6 years, so it is not possible to determine the superiority.
현대의학에 의하여 증명된 인삼 및 홍삼의 효능은 항상성 효과, 안전무독, 저항력 증진작용, 내분비 조절작용, 혈압조절, 대사 촉진, 소염, 쇠약 회복, 능률조절, 신경안정, 수명연장, 혈관강화, 조혈작용, 건위, 강정, DNA 합성, 항암, 정자증진, 항당뇨, 성장촉진 등으로 만병을 다스리는 통치약으로 일컬어지고 있을 정도이다. 이와 같은 효능을 가진 인삼은 산지별, 연근별, 대소별, 형태별, 부위별, 등급별로 분류하고 상호간에 깊은 관계를 가지고 있다. 인삼은 의약품과 식품으로 구분하여 기능과 책임에 따라 분류하며 치료와 예방이라는 목적으로 사용할 때는 약으로, 또 조건이 완화된 가공식품으로는 인삼차, 인삼주, 인삼과자 등의 식품 또는 건강보조 식품으로 구분하여 관리되고 있다. 인삼의 가공 목적은 건조되지 아니한 수삼은 80∼85%에 해당하는 수분으로 장기 저장이 불가능하여 백삼 또는 홍삼 등으로 장기보존을 목적으로 가공되어 왔고 1894년 대한제국 탁지부에서 홍삼을 전 매법으로 보호한 바 있다.The efficacy of ginseng and red ginseng certified by modern medicine has homeostatic effects, safety toxic effects, resistance enhancement, endocrine control, blood pressure control, metabolism promotion, anti-inflammatory, weakness recovery, efficiency control, nerve stability, life extension, blood vessel strengthening, hematopoiesis It is said to be a ruling medicine that controls all diseases with action, health, strength, DNA synthesis, anti-cancer, sperm promotion, anti-diabetes, and growth promotion. Ginseng having such efficacy is classified by mountain, lotus root, small and large, form, part, grade, and has a deep relationship with each other. Ginseng is divided into medicines and foods and classified according to their function and responsibility.They are used as medicines for the purpose of treatment and prevention, and processed foods with relaxed conditions are classified as foods such as ginseng tea, ginseng wine, ginseng confectionery or health supplement foods. Are managed. For the purpose of processing ginseng, undried ginseng is 80 ~ 85% of moisture, which can not be stored for a long time, and has been processed for long-term preservation such as white or red ginseng. There is a bar.
홍삼차는 홍삼을 추출하고 농축하여 엑기스를 이용한 추출차, 분말을 이용한 분말차 등으로 구분하여 관리되어 왔다. 홍삼차의 대표적인 것은 추출 과립차로서 홍삼 추출액을 농축시켜 포도당 및 유당에 혼합하여 과립 성형시켜 건조시킨 것으로, 당류를 담체로 하여 과립 성형화한 것이어서 현대인의 당류 기피현상으로 인해 그 기호성이 점점 상실되어 가고 있다. 이러한 현실을 감안하여 고려 홍삼의 우수성과 국익을 위하여 당이 없는 홍삼 침출차의 발명에 착안하여, 시대가 요구하는 기능성 차를 발명하고자 하였다. 또한, 사포닌의 함량이 높게 함유하고 있으면서도 별다른 제조방법이 없어서 폐기되어 왔던 인삼의 잔뿌리를 이용하여 인삼차를 개발하고자 하는 것이 본 발명자가 발명에 착수하게 된 계기가 되었다. 일반 홍삼은 그 주근부나 미근부 등을 물에 끊여서는 사포닌을 100% 용출할 수가 없어서, 기존에는 에탄올로 용출해야만 했기 때문에, 일반인들이 쉽게 차를 만들어 먹기가 어려웠고, 그만큼 제조 비용이 높기 때문에 소비자가 구입하는 비용도 크게 비싸다는 문제점이 있었다.Red ginseng tea has been managed by extracting and concentrating red ginseng into extract tea using extract and powder tea using powder. Representative of red ginseng tea is extract granulated tea, which is concentrated red ginseng extract, mixed with glucose and lactose, granulated and dried, and granularly molded with sugar as a carrier, and its palatability is gradually lost due to the avoidance of sugars in modern people. have. Considering this reality, the inventors of the invention focused on the invention of red ginseng leaching tea without sugar for the sake of excellence and national interest of Korean red ginseng. In addition, the present inventors have attempted to develop a ginseng tea using the small roots of ginseng, which had been discarded due to the high content of saponin but no manufacturing method. In general, red ginseng can not elute 100% of saponin by cutting its roots and tails in water, so it has been difficult to make tea easily because ordinary people had to elute it with ethanol. There was a problem that the cost of purchasing is also very expensive.
본 발명에서 홍삼을 담그는 침윤제로 사용하는 약제 중에서 황기는 강장작용, 면역기능조절작용, 강심이뇨 작용, 혈압강하작용 및 소염작용이 있으며 몸을 보호하는 약제로서 신체허약, 자한, 종기, 지갈, 음식무미 및 식욕부진에 유효하고 여성들에게는 자궁출혈, 부인대하, 월경불순 및 산전산후 일절병에 유효하며 에이즈, 암, 종양과 같은 면역 결핍 질병에 효과가 있고 만성 폐질환에도 좋다. 사삼은 보증, 익기, 화담 및 지혜의 효능이 있으며 진해, 거담, 강장약으로서 감기나 폐질 환의 거담제, 강장 및 배농제로 사용한다. 맥문동은 양음윤폐, 청심제번 및 양위생진의 효능이 있으며 자강강장약, 진해, 거담, 강심, 혈당강하작용 및 항염증작용이 있다. 복령은 강장, 이뇨 및 진정에 효능이 있어 신장병, 방광염, 요도염에 이용되고 소화성 궤양, 근육경련, 갈증, 현훈, 정신불안, 실면증에 효과적이며 접촉성 피부염 억제작용이 있다. 건강은 위액 분비 촉진과 장관의 연동 작용을 활성화시키므로 소화를 돕고 구토를 가라앉히는 효과를 나타내며 혈관운동 충추, 호흡 증추와 심장 흥분 작용이 있어서 혈액순환을 촉진시키며 항염증 작용 및 진통 작용이 있고 항균 작용을 나타낸다.In the present invention, the drug used as an infiltrating agent to soak red ginseng has tonic action, immune function control action, cardiac diuresis action, blood pressure lowering action and anti-inflammatory action and body protection agent, body weakness, jahan, boil, jigal, food It is effective for tastelessness and anorexia, and is effective for women with uterine bleeding, gynecological disorders, menstrual irregularities and postpartum maternal disease. Samsam has the effect of guarantee, ripening, talk and wisdom. It is used as an expectorant, tonic and fertilizer for colds and lung diseases as antitussive, expectorant and tonic. McMoon-Dong has the efficacy of Yang Yin Yun Pung, Cheongshimjeung and Yang San Sengjin, and has Jagangang, Jinhae, sputum, cardiac, hypoglycemic action and anti-inflammatory action. Bokryeong is effective in tonic, diuretic and sedative, and is used for kidney disease, cystitis and urethritis. It is effective for peptic ulcer, muscle cramps, thirst, vertigo, mental anxiety and insomnia, and inhibits contact dermatitis. Health promotes secretion of gastric juice and activates the peristalsis of the intestinal tract, which helps digestion and calms vomiting. Indicates.
본 발명은 상기한 종래 기술의 문제점을 해소하기 위한 것으로서, 사포닌의 함량을 높게 함유하고 있는 홍삼을 가공하여 물에 끊여서 보다 많은 양의 사포닌을 용출시킬 수 있도록 한 흑진삼 제조방법을 제공하는 데 있다.The present invention is to solve the above problems of the prior art, and to provide a method for producing black ginseng that can be eluted in a larger amount of saponin by cutting off red ginseng containing a high content of saponin in water. .
본 발명은 물, 에탄올, 메탄올, 이소프로판올로 이루어진 그룹 중에서 선택되는 하나 이상의 용매에 황기 20중량%, 사삼 20중량%, 오가피 20중량%, 맥문동 17 중량%, 복령 16 중량% 및 건강 7 중량%를 넣고 60∼70℃로 3∼6시간 동안 1차 증숙시킨 후 135℃의 온도로 약 3∼6시간 동안 고압 증숙하고 가열농축하여 5 브릭스(Brix)의 농축액을 제조하는 1공정 단계; 상기 농축액에 홍삼을 담구어 하룻밤동안 침윤시킨 후 가마솥 증숙기에서 온도 60∼70℃로 3∼6시간 동안 1차 증숙시킨 후, 70∼75℃의 황토건조실에서 수분량이 28%에 도달할 때까지 건조시키는 2공정 단계; 상기 2공정 단계를 다시 4회에 걸쳐 반복하는 3공정 단계; 상기 3공정 단계를 완료한 흑진삼을 고압증숙기에서 135℃의 온도로 약 3∼6시간 동안 고압 증숙하고, 맥반석 열풍회전건조기에서 60∼70℃의 온도로 수분 25%까지 건조시키는 4공정 단계; 상기 4공정을 다시 4회에 걸쳐 반복하는 5공정 단계: 및 상기 5공정 단계를 완료한 흑진삼을 벌크건조기에서 최종 수분함량 14%로 건조하는 6공정 단계를 포함하는 것을 특징으로 하는 흑진삼의 제조방법에 관한 것이다.The present invention provides 20% by weight of sulfur, 20% by weight of ginseng, 20% by weight of Ogapi, 17% by weight of Macmundong, 16% by weight of Bokryeong and 7% by weight of at least one solvent selected from the group consisting of water, ethanol, methanol and isopropanol. First step of steaming for 3 to 6 hours at 60 to 70 ° C., and then steaming at high pressure for about 3 to 6 hours at a temperature of 135 ° C. and heating to prepare a concentrated solution of 5 Brix; After soaking red ginseng in the concentrate for 1 night and steaming for 1 to 3 hours at 60-70 ° C in a cauldron steamer until the water content reaches 28% in 70-75 ° C ocher drying room. Two process steps of drying; Three process steps of repeating the two process steps four times again; The black ginseng, which has completed the three process steps, is steamed at a high pressure steamer at a temperature of 135 ° C. for about 3 to 6 hours, and dried at 25 to 60% water at a temperature of 60 to 70 ° C. in an elvan rock hot air dryer. ; Five process steps of repeating the above four steps four times: and six process steps of drying the black ginseng, which has completed the five process steps, to a final moisture content of 14% in a bulk dryer. It relates to a manufacturing method.
이하, 본 발명에 따른 흑진삼 제조방법 및 그를 이용하여 제조된 흑진삼에 대해 상세히 설명한다. 본 발명의 주된 기술내용은 사포닌의 함량이 가장 높은 홈삼을 최적으로 가공하여 흑진삼을 제조함으로써, 일반인들이 흑진삼을 간단하게 물에 끊여도 높은 사포닌이 함유된 인삼차를 음용할 수 있도록 하는 것이다. Hereinafter, a method for preparing black ginseng and the black ginseng prepared by using the same according to the present invention will be described in detail. The main technical content of the present invention is to produce black ginseng by optimally processing the ginseng with the highest content of saponin, so that ordinary people can drink ginseng tea containing high saponin even if the black ginseng is simply cut off in water.
인삼은 몸통부에 해당하는 주근부와 잔뿌리에 해당하는 미근부로 구분되는데, 일반적으로 주근부보다 미근부에 사포닌의 함량이 높게 함유되어 있다. 인삼의 주근부는 가공처리후의 색도에 따라 백미삼, 홍미삼 및 흑진삼으로 구분될 수 있는데, 본 발명에 따라서 제조된 흑삼은 흑색을 띠기 때문에 흑진삼으로 명명하도록 하겠다. 본 발명에 따른 흑진삼은 홍삼을 가마솥 증숙기에서 60∼70℃로 3~6시간 동안 1차 증숙한 후, 70∼75℃의 온도로 맞추어 수분함량이 28%에 도달할 때까지 건조한다. 상기 흑진삼을 상기 제 1공정과 동일한 방법으로 다시 4회에 걸쳐 반복하여 제조한다. 총 5회에 걸쳐 제 1공정을 완료한 흑진삼을 고압증숙기에서 135℃의 온도로 약 3∼6시간 동안 고압 증숙하고, 맥반석 열풍회전건조기에서 60∼70℃에서 수분 25%까지 건조시키는 공정을 수행한다. 또한, 상기 공정에서 제조된 흑진 삼을 상기 제 2공정과 동일한 방법으로 다시 4회에 걸쳐 반복제조한다. 상기 공정으로 제조된 흑삼을 증숙 및 건조를 반복하여 제조하고 제조한 흑진삼을 벌크건조기에서 최종 수분함량 14%로 건조한 후, 이물질을 제거하여 완제품의 흑진삼을 제조한다.Ginseng is divided into the main root portion corresponding to the trunk and the tail root corresponding to the root root. Generally, the content of saponin is higher in the tail portion than the main root portion. The main root of ginseng may be divided into white and red ginseng and black ginseng according to the chromaticity after processing. The black ginseng prepared according to the present invention will be named black ginseng because it has black color. Black ginseng according to the present invention first steamed red ginseng at 60-70 ° C. for 3-6 hours in a cauldron steamer, and then dried at a temperature of 70-75 ° C. until the water content reaches 28%. The black ginseng is repeatedly produced four times in the same manner as in the first step. The black ginseng, which has completed the first step five times, is steamed at a high pressure steamer at a temperature of 135 ° C. for about 3 to 6 hours, and dried to 25% moisture at 60 to 70 ° C. in an ganbanite hot air rotary dryer. Do this. In addition, the black ginsam produced in the above process is repeatedly produced four times in the same manner as in the second process. The black ginseng prepared by the above process is repeatedly steamed and dried, and the prepared black ginseng is dried with a final moisture content of 14% in a bulk dryer, and then foreign matters are removed to prepare black ginseng.
실시예 1Example 1
물과 에탄올을 1: 1 동일한 중량비율로 혼합한 용매에 황기 20g, 사삼 20g, 오가피 20g, 맥문동 17g, 복령 16g 및 건강 7g을 넣고 60℃로 3시간 동안 1차 증숙시킨 후 135℃의 온도로 약 3시간 동안 고압 증숙하고 가열농축하여 5 브릭스(Brix)의 농축액을 제조하였다. 상기 농축액에 홍삼 100g을 담구어 하룻밤동안 침윤시킨 후 가마솥 증숙기에서 온도 60℃로 3시간 동안 1차 증숙시킨 후, 70℃의 황토건조실에서 수분량이 28%에 도달할 때까지 건조시켰다. 상기 공정 단계를 다시 4회에 걸쳐 반복하고 고압증숙기에서 135℃의 온도로 약 3시간 동안 고압 증숙하고, 맥반석 열풍회전건조기에서 60℃의 온도로 수분 25%까지 건조시켰다. 상기 공정을 다시 4회에 걸쳐 반복하고 벌크건조기에서 최종 수분함량 14%로 건조하여 흑진삼 90g을 제조하였다.In a solvent mixed with water and ethanol in the same weight ratio of 1: 1, 20 g of Astragalus, 20 g of Samsam, 20 g of Ogapi, 17 g of Bokyeong-dong, 16 g of Bokryeong, and 7 g of health were first steamed at 60 ° C. for 3 hours and then heated to 135 ° C. High pressure steaming and heat concentration for about 3 hours to prepare a 5 Brix concentrate. 100 g of red ginseng was soaked in the concentrate and infiltrated overnight, followed by primary steaming at a temperature of 60 ° C. for 3 hours in a cauldron steamer, and then dried until the amount of water reached 28% in an ocher drying chamber at 70 ° C. The process steps were repeated four more times and steamed at high pressure for about 3 hours at a temperature of 135 ° C. in a high pressure steamer, and dried at a temperature of 60 ° C. at a temperature of 60 ° C. in a ganbanite hot air rotary dryer. The process was repeated four more times and dried to a final moisture content of 14% in a bulk dryer to prepare 90 g of black ginseng.
실험예 1Experimental Example 1
본 발명의 방법으로 제조한 흑진삼을 중앙대학교 인삼산업연구소에 의뢰하여 사포닌의 함량을 분석하였다. Black ginseng prepared by the method of the present invention was commissioned by the ginseng industry research institute of Chung-Ang University to analyze the content of saponin.
◈ 실험 방법 ◈ Experiment Method
1. 구증 1. Guobi
Sample 100g(분말화)을 95% EtOH 2시간동안 2회 열추출 후 농축하여 식품공전법의 흑삼 성분법에 의한 전처리 후 HPLC 분석하였다. 시험결과는 표1에 나타났다. 100 g (powdered) of the sample was 95% EtOH for 2 hours after heat extraction and concentrated and analyzed by HPLC after pretreatment by the black ginseng component method of the food method. The test results are shown in Table 1.
2. 구증+주증3회 2. Guobi + 3rd Note
Sample 100g(분말화), 95% EtOH 2시간동안 2회 열 추출 후 농축하여 식품공전법의 흑삼 성분법에 의한 전처리 후 HPLC 분석하였다. 시험결과는 표2에 나타났다. Sample 100g (powdered), 95% EtOH 2 hours after the heat extraction for 2 hours, concentrated and analyzed by HPLC after pretreatment by the black ginseng component method of the food method. The test results are shown in Table 2.
3. 주증4회 3. 4 times
Sample 100g(분말화), 95% EtOH 2시간동안 2회 열 추출 후 농축하여 식품공전법의 흑삼 성분법에 의한 전처리 후 HPLC 분석하였다. 시험결과는 표3에 나타났다. Sample 100g (powdered), 95% EtOH 2 hours after the heat extraction for 2 hours, concentrated and analyzed by HPLC after pretreatment by the black ginseng component method of the food method. The test results are shown in Table 3.
◈ HPLC 분석 조건 ◈ HPLC analysis condition
1. Mobile Phase 1. Mobile Phase
Solvent A - ACN : Water : IPA = 80 : 5 : 15 Solvent A-ACN: Water: IPA = 80: 5: 15
Solvent B - ACN : Water : IPA = 67 : 21 : 12 Solvent B-ACN: Water: IPA = 67: 21: 12
2. Gradient 2. Gradient
3. Flow rate : 0.8 ㎎/㎖ 3.Flow rate: 0.8 ㎎ / ㎖
4. Detector : ELSD 2000ES 4. Detector: ELSD 2000ES
5. Column : Prevail Carbohydrate ES column 5.Column: Prevail Carbohydrate ES column
표 1.Table 1.
표 2.Table 2.
표 3.Table 3.
실험예 2Experimental Example 2
본 발명의 방법으로 제조한 흑진삼의 효과를 확인하기 위하여 충청남도 금산의 동일지역에서 함께 재배한 4년생의 인삼을 같은 시기에 채취, 이를 원료삼으로 사용하였다. 하기 표 4에는 상기와 같은 제조방법에 의하여 제조한 본 발명에 따른 흑진삼과 홍삼근의 사포닌 성분을 비교한 결과가 기재되어 있다.In order to confirm the effect of black ginseng prepared by the method of the present invention, the four-year-old ginseng cultivated together in the same region of Geumsan, Chungcheongnam-do was collected at the same time, and used as raw ginseng. Table 4 below shows the results of comparing the saponin components of the black ginseng and red ginseng root according to the present invention prepared by the manufacturing method as described above.
표 4. 흑진삼과 홍삼근의 성분비교표Table 4. Composition of Black Ginseng and Red Ginseng Root
상기 표 4에 기재된 바와 같이, 본 발명에 따라 제조된 흑진삼의 사포닌 성 분들의 함량을 보면 홍삼근 보다도 모든 성분에서 크게 높게 나타남을 볼 수 있다. 본 발명에 따라 제조된 흑진삼은 상기의 성분들이 물에 끊였을 때에 거의 대분분이 용출되기 때문에, 그 약리적인 효과도 다른 제품들보다 월등히 높은 것이다.As shown in Table 4, the saponin content of the black ginseng prepared according to the present invention can be seen to be significantly higher in all components than the red ginseng root. Black ginseng prepared according to the present invention is almost eluted when the above components are suspended in water, the pharmacological effect is significantly higher than other products.
본 발명의 흑진삼 성분의 약리작용을 살펴보면 Ginsenosides-Rg3는 암세포전이 억제작용, 혈소판 응집억제 및 항혈전작용, 실험적 간 상해 억제작용, 혈관이완 작용, 항암제의 내성 억제작용을 하고, Ginsenosides-Rg2는 혈소판 응집억제, 항트롬빈, 선용활성화작용, 기억감퇴 개선, 평활근세포 증식억제작용, 아세칠콜린 유도, 카레콜아민 분비 억제 및 세포내 칼슘 유입 억제작용을 하고, Ginsenosides-Rg1는 면역기능 증강작용, 혈소판응집억제, 항트롬빈, 선용활성화 작용, 기억 및 학습기능증진작용, 코티코스테로이드 수용체 활성화 작용, 단백질합성 촉진작용, 항피로 작용, 항스트레스 작용, 중추 흥분작용, 혈관 확장작용 및 내인성 발열물질 등 유해자극 방어작용, 스트레스성 성행동장해 개선작용, 항신염 작용 및 신혈류량 증대작용, 신경세포 생존율 촉진작용, 콜레스테롤 대사 촉진작용, 항염증 작용, 간세포 증식 및 DNA 합성촉진, 간장해 보호작용, 부신피질자극 호르몬 분비 촉진작용을 하고, Ginsenosides-Rf는 통증억제 작용, 지질과산화 억제작용, 알코올 유도 뇌발육 장해 방어작용을 하고, Ginsenosides-Re는 부신피질 자극호르몬, 코티코스테론 분비촉진, 골수세포의 DNA, RNA, 단백질, 지질합성 촉진작용, 진통작용, 평할근 세포증식억제, 혈관 확장작용, 콜레스테롤 대사 촉진작용, 간 상해 보호작용, 항 고온스트레스 작용을 하고, Ginsenosides-Rd는 부신피질 자극호르몬, 코티코스테론 분비 촉진작용, mesanchyme 세포증식 억제를 하고, Ginsenosides-Rc는 진통작용, 코티코스테론 분비 촉진작용, PGI2 생성 촉진작용, 간, 혈청콜레스테롤, RNA 합성촉진작용, 골수세포 DNA, RNA, 단백질 및 지질합성 촉진작용, mesenchyme 세포증식억제 작용을 하고, Ginsenosides-Rb2는 당 및 지방대사 촉진, 항당뇨 작용, ACTHcAMP, epinephrine유도 지방분해 억제작용, 질소대사 평형 유지작용, 고콜레스테롤 저하 및 항동맥경화 작용, DNA, RNA, 부신피질 자극 호르몬, 코티코스테론 분비 촉진작용, 단백질, 지질합성 촉진작용, 암독소 호르몬의 길항작용, 평활근 세포 증식 억제작용, 종양혈과 stlstod 억제작용, 스트레스성 식욕 감퇴 개선, 항산화 활성물질 생성 촉진작용, 간조직의 ATP공급 활성화 작용, ATP함량 증가, 진통작용을 하고, Ginsenosides-Rb1는 중추억제 및 정신안정 작용, 중추성 섭식 억제작용, 공격성 행동억제, 진통작용, 항경련작용, 부신피질자극호르몬 및 코티코스테론 분비 촉진작용, 항불안작용, 콜레스테롤 생합성 촉진작용, 고콜레스테롤과 중성지방 및 유리지방산의 저하작용, 골수세포의 DNA, RNA, 단백질 및 지질합성 촉진작용, 단백질합성 촉진작용, 신경세포 생존 촉진작용, 아세칠 콜린 방출 촉진작용, 기억력 개선작용, 혈소판 응집 억제작용, 지질과산화 억제작용, 혈관확장작용, 콜레스테롤 대사 촉진작용, 항염증 작용, 간 상해 보호작용, 사염화탄소 유도, 간의 단백질 인산화 억제 및 세포내 칼슘축적 억제작용, 탐식기능 활성화 작용을 하며, Ginsenosides-Rh1는 실험적 간 상해 억제작용, 종양세포분화촉진, 혈소판 응집억제 및 선용활성화 작용 을 하고, Ginsenosides-Rh2는 암세포증식 억제작용, 암세포 재분화 유도 촉진작용, 암세포 침윤 억제작용, 종양증식 억제작용, 항암제의 항암활성 증대작용을 한다.Looking at the pharmacological action of the black ginseng component of the present invention Ginsenosides-Rg 3 inhibits cancer cell metastasis, inhibits platelet aggregation and antithrombotic action, experimental liver injury inhibitory action, vascular relaxation action, anti-cancer drug resistance, Ginsenosides-Rg 2 inhibits platelet aggregation, antithrombin, gland activation, memory loss, smooth muscle cell proliferation inhibition, acylcholine induction, currycolamine secretion and intracellular calcium influx, Ginsenosides-Rg 1 Enhancer, platelet aggregation inhibitory, antithrombin, glandular activation, memory and learning function, corticosteroid receptor activation, protein synthesis promotion, antifatigue, antistress, central excitability, vasodilation and endogenous fever Defense against harmful stimuli such as substances, improving stressful sexual behavior disorders, anti-nephritis and renal blood flow, promoting neuronal survival Ginsenosides-Rf inhibits pain, inhibits lipid peroxidation, alcohol-induced brain development, and promotes cholesterol metabolism, anti-inflammatory, hepatic cell proliferation and DNA synthesis, hepatic impairment protection, and corticosteroid secretion. Ginsenosides-Re acts as a defense against corticosteroids, corticosteroid secretion, bone marrow cell DNA, RNA, protein, lipid synthesis, analgesic activity, flat muscle cell proliferation inhibition, vasodilation, cholesterol metabolism Ginsenosides-Rd promotes adrenal cortical stimulating hormone, corticosteroid secretion, mesanchyme cell proliferation, Ginsenosides-Rc promotes analgesic and corticosteroid secretion Action, PGI 2 production promotion, liver, serum cholesterol, RNA synthesis promotion, bone marrow cell DNA, RNA, protein and lipid synthesis promotion, mesenchyme cell proliferation Ginsenosides-Rb 2 promotes glucose and fat metabolism, antidiabetic action, ACTHcAMP, epinephrine-induced lipolysis, nitrogen metabolism equilibrium, high cholesterol and anti-arteriosclerosis, DNA, RNA, adrenal cortex Stimulating hormone, stimulating corticosteroid secretion, stimulating protein, lipid synthesis, antagonism of cancer toxin hormone, inhibiting smooth muscle cell proliferation, inhibiting tumor blood and stlstod, improving stress appetite loss, promoting antioxidant active substance production, ATP supply activation of liver tissue, increased ATP content, analgesic action, Ginsenosides-Rb 1 is central and anti-stable, central feeding, inhibitory action, analgesic, anticonvulsant, adrenal cortex stimulating hormone And corticosterone secretion, anti-anxiety, cholesterol biosynthesis, high cholesterol and triglycerides and free fatty acids, bone marrow cells DNA, RNA, Promote protein and lipid synthesis, Promote protein synthesis, Promote nerve cell survival, Promote acetylcholine release, Improve memory, Inhibit platelet aggregation, Inhibit lipid peroxidation, Vasodilation, Promote cholesterol metabolism, Anti-inflammatory Action, protect liver injury, induce carbon tetrachloride, inhibit liver protein phosphorylation and inhibit intracellular calcium accumulation, activate phagocytosis. Ginsenosides-Rh 1 inhibits experimental liver injury, promotes tumor cell differentiation, inhibits platelet aggregation and uses Activation action, Ginsenosides-Rh 2 has the effect of inhibiting cancer cell proliferation, promoting the induction of cancer cell regeneration, inhibiting cancer cell invasion, inhibiting tumor proliferation, anticancer activity.
상기에 언급한 바와 같이, 본 발명의 흑진삼 제조방법에 따르면 용매에 황기 20중량%, 사삼 20중량%, 오가피 20중량%, 맥문동 17 중량%, 복령 16 중량% 및 건강 7 중량%를 넣고 가열농축한 농축액에 홍삼을 침윤시킨 후 증숙 및 건조를 9회 이상 반복하여 보다 많은 사포닌을 함유하는 흑진삼을 제조할 수 있으며, 그렇게 해서 제조된 흑진삼에는 다른 홍삼근 보다도 높은 함량의 사포닌을 함유할 수 있도록 한다. 한편, 상기에서는 본 발명의 바람직한 실시예들을 참조하여 설명하였지만, 해당 기술분야에서 통상의 지식을 가진 자라면 하기의 청구의 범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다. As mentioned above, according to the method for producing black ginseng according to the present invention, 20% by weight of sulfuric acid, 20% by weight of Sasam ginseng, 20% by weight of Ogapi, 17% by weight of Macmundong, 16% by weight of Bokryeong, and 7% by weight of health are heated. After infiltrating red ginseng into the concentrated concentrate, steaming and drying can be repeated nine times or more to produce black ginseng containing more saponins, and the black ginseng thus prepared can contain a higher content of saponins than other red ginseng roots. Make sure On the other hand, while the above has been described with reference to the preferred embodiments of the present invention, those skilled in the art to which the present invention pertains without departing from the spirit and scope of the present invention described in the claims below It will be understood that modifications and changes can be made.
Claims (2)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050112633A KR101234605B1 (en) | 2005-11-24 | 2005-11-24 | Manufacturing method of black rootlets of ginseng |
PCT/KR2006/001407 WO2007061162A1 (en) | 2005-11-24 | 2006-04-17 | Black rootlets of ginseng and process for preparing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050112633A KR101234605B1 (en) | 2005-11-24 | 2005-11-24 | Manufacturing method of black rootlets of ginseng |
Publications (3)
Publication Number | Publication Date |
---|---|
KR20070054764A true KR20070054764A (en) | 2007-05-30 |
KR101234605B1 KR101234605B1 (en) | 2013-02-22 |
KR101234605B9 KR101234605B9 (en) | 2021-11-19 |
Family
ID=38067367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050112633A KR101234605B1 (en) | 2005-11-24 | 2005-11-24 | Manufacturing method of black rootlets of ginseng |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101234605B1 (en) |
WO (1) | WO2007061162A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100864471B1 (en) * | 2007-04-25 | 2008-10-20 | 김재경 | A processed ginseng using extract of herb medicine and a producing method thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101593618B1 (en) * | 2009-05-26 | 2016-02-15 | (주)아모레퍼시픽 | Composition for improving bioavailability of saponin |
CN103404675A (en) * | 2013-08-30 | 2013-11-27 | 黑龙江省新曙光刺五加生物科技开发有限公司 | Acanthopanax senticosus tea for preventing flu and preparation method thereof |
KR102411106B1 (en) * | 2022-02-11 | 2022-06-22 | 대동고려삼 주식회사 | Method for producing black ginseng concentrate with increased prosapogenin ginsenoside content using continuous steaming-drying technique and combined concentration technology |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3782122B2 (en) * | 1994-04-11 | 2006-06-07 | サンスター株式会社 | Metabolism promoter for oral intake and food containing the same |
MY124001A (en) * | 1999-04-23 | 2006-06-30 | E Excel Int | Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice |
KR20030012714A (en) * | 2001-08-04 | 2003-02-12 | 양상철 | a making method for growth food |
KR20030081930A (en) * | 2002-04-15 | 2003-10-22 | 이규환 | A marking method of red ginseng jam used the red ginseng by main raw material and therefore red ginseng jam |
KR100496418B1 (en) | 2002-09-11 | 2005-06-28 | 한국파낙스제조(주) | Manufacturing method of black rootlets of ginseng |
KR20040063741A (en) * | 2003-01-08 | 2004-07-14 | 김종호 | This method and manufacturing of wild red-ginseng using wild ginseng |
KR100543862B1 (en) | 2005-08-01 | 2006-01-23 | (주) 흑삼코리아 | A black ginseng having excel content of active ingredient and the concentrate of black ginseng |
KR100600795B1 (en) | 2006-01-18 | 2006-07-19 | (주) 흑삼코리아 | A black ginseng having excel content of ginsenoside rg3 ingredient and the concentrate of black ginseng |
KR100864471B1 (en) | 2007-04-25 | 2008-10-20 | 김재경 | A processed ginseng using extract of herb medicine and a producing method thereof |
-
2005
- 2005-11-24 KR KR1020050112633A patent/KR101234605B1/en active IP Right Grant
-
2006
- 2006-04-17 WO PCT/KR2006/001407 patent/WO2007061162A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100864471B1 (en) * | 2007-04-25 | 2008-10-20 | 김재경 | A processed ginseng using extract of herb medicine and a producing method thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2007061162A1 (en) | 2007-05-31 |
KR101234605B1 (en) | 2013-02-22 |
KR101234605B9 (en) | 2021-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107467650B (en) | Red date donkey-hide gelatin cake and preparation method thereof | |
KR100496418B1 (en) | Manufacturing method of black rootlets of ginseng | |
CN104946453B (en) | A kind of production method of health care medicinal wheat koji | |
CN103740566B (en) | Rosa roxbunghii medicinal liquor and preparation method thereof | |
CN103610065A (en) | Sea cucumber and maca composition and preparation method thereof | |
CN105695258A (en) | Female health wine containing lychee seed saponin | |
CN101724667A (en) | Technology for extracting dendrobium polysaccharide by applying biology engineering enzyme technology and product thereof and application | |
CN104970421A (en) | Longan and donkey-hide gelatin powder composite solid drink | |
KR101234605B1 (en) | Manufacturing method of black rootlets of ginseng | |
CN107333926A (en) | A kind of Seabuckthorn healthcare tea and its preparation technology | |
KR102042798B1 (en) | A method for preparing functional pills comprising extracts of natural materials | |
CN104739977A (en) | Maca health wine/tablet with function of strengthening primordial qi | |
CN107432911B (en) | Ginseng buccal tablet for preserving health and tonifying kidney and preparation method thereof | |
CN112220885A (en) | Traditional Chinese medicine composition for protecting gastric mucosa and preparation method and application thereof | |
CN112704717A (en) | Stomach-invigorating medicinal and edible composition for assisting treatment of advanced digestive tract tumor | |
CN103734767A (en) | Health-care food | |
KR101095357B1 (en) | Processed Ginseng | |
CN110810693A (en) | A beverage composition containing Ampelopsis grossedentata and its preparation method | |
CN101248877A (en) | Anti-senescence functional food product and method for preparing the same | |
KR102436045B1 (en) | Fermented black ginseng composition prepared using yeast fermentation broth containing medicinal herbs and minerals and manufacturing method thereof | |
CN113679051A (en) | Peony polypeptide powder, solid beverage and application thereof | |
CN108355052B (en) | Medicine for treating leucopenia after radiotherapy and chemotherapy and preparation method and application thereof | |
CN112076292A (en) | Powder with functions of enhancing immunity and regulating kidney yin deficiency and preparation method thereof | |
KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
CN112402569A (en) | Anti-fatigue health product and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160212 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170213 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180213 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190212 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20200213 Year of fee payment: 8 |